(lp0
S"Judge puts Seattle Genetics' $2 billion deal with Immunomedics on hold Puget Sound Business Journal  - Mar 9, 2017 17, Immunomedics sued shareholder VenBio for attempting to take over Immunomedics' board and kill the licensing deal with Seattle Genetics. VenBio had a 9.9 percent stake in Immunomedics at the the time of the lawsuit. VenBio says the Seattle Genetics&nbsp;...Seattle Genetics, Inc.  Files An 8-K Other Events - Market ExclusiveImmunomedics' IMMU-132 deal on hold; shares rally 11%; Seattle Genetics down a ... - Seeking Alpha"
p1
aS"Seattle Genetics  Up 8.2% Since Earnings Report: Can It Continue? Zacks.com - Mar 14, 2017 Seattle Genetics continues to work on expanding Adcetris' label further. The company.Takeda released full data from the ALCANZA phase III study in patients with CD30-expressing cutaneous T-cell lymphoma  in Dec 2016."
p2
aS'Seattle Genetics to resume trials as FDA lifts clinical hold Daily Mail - Mar 6, 2017 March 6  - Seattle Genetics Inc said on Monday the U.S. Food and Drug Administration lifted a clinical hold on several early stage studies testing its experimental cancer drug.FDA lifts hold on Seattle Genetics drug trials - ReutersSeattle Genetics : FDA Lifts Hold on Trial of AML Drug - Yahoo Finance'
p3
aS'Bear of the Day: Seattle Genetics  Yahoo Finance - Feb 24, 2017 SGEN, a Zacks Ranked #5 , is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer.Seattle Genetics Inc Risk Points versus Health Care - CML News'
p4
aS'March 13 Deadline Alert: Law Offices of Howard G. Smith Reminds Seattle ... Yahoo Finance - Mar 10, 2017 Law Offices of Howard G. Smith reminds investors of the upcoming March 13, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of a class of investors who purchased or otherwise acquired Seattle Genetics, Inc. (Seattle ...'
p5
aS"Analyst's Predictions on Moleculin Biotech, Inc. , Seattle Genetics, Inc ... StockNewsJournal - 18 hours ago Seattle Genetics, Inc. , at its latest closing price of $61.95, it has a price-to-book ratio of 15.25, compared to an industry average at 10.15."
p6
aS'Hot Stocks Report: BorgWarner Inc. , Seattle Genetics, Inc.  Post Analyst - 15 hours ago Turning to Seattle Genetics, Inc. , its shares were trading at $61.95 a retreat of $-6.07, on the trading floor.'
p7
aS'SHAREHOLDER ALERT: Levi &amp; Korsinsky, LLP Reminds Shareholders of Seattle ... Yahoo Finance - Mar 3, 2017 To: All persons or entities who purchased or otherwise acquired securities of Seattle Genetics Inc.   between October 27, 2016 and December 23, 2016.'
p8
aS'EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action ... PR Newswire  - Mar 2, 2017 NEW YORK, March 2, 2017 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Seattle Genetics Inc. securities  from October 27, 2016 through&nbsp;...'
p9
aS"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on ... GlobeNewswire  - Feb 28, 2017 NEW YORK, Feb. 27, 2017  -- Pomerantz LLP announces that a class action lawsuit has been filed against Seattle Genetics Inc.   and certain of its officers. The class action, filed in&nbsp;...Next Weeks Broker Price Targets For Seattle Genetics, Inc.  - Fiscal StandardThe Seattle Genetics   Investment Analysts' Recent Ratings Changes - DailyQuint"
p10
a.